Subclinical reduced G6PD activity in rheumatoid arthritis and Sjögren's Syndrome patients: Relation to clinical characteristics, disease activity and metabolic syndrome

Modern Rheumatology

Volumn 24, Issue 4, 2014, Pages 612-617

  Gheita, Tamer Atef ^a   Kenawy, Sanaa Abdel Baky ^b   El Sisi, Rehab Wafik ^c   Gheita, Heba Atef ^d   Khalil, Hossam ^e  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c MSA University   (Egypt)

^d HOT LABORATORIES CENTER   (Egypt)

^e BENI SUEF UNIVERSITY   (Egypt)

Author keywords

DAS28; G6PD activity; Metabolic syndrome; Rheumatoid arthritis; Sj gren's Syndrome

Indexed keywords

CORTICOSTEROID; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE COUNT; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SJOEGREN SYNDROME DISEASE ACTIVITY INDEX; SJOEGREN SYNDROME DISEASE DAMAGE INDEX; ARTHRITIS, RHEUMATOID; COMPLICATION; ENZYMOLOGY; METABOLISM; SJOGREN'S SYNDROME;

ADULT; ARTHRITIS, RHEUMATOID; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; MALE; METABOLIC SYNDROME X; SJOGREN'S SYNDROME;

EID: 84903732248     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.851639     Document Type: Article

References (41)

1. Leopold JA, Zhang Y, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol. 2003;23(3):411-7.
2. Gupte RS, Ata H, Rawat D, Abe M, Taylor MS, Ochi R, Gupte SA. Glucose-6-phosphate dehydrogenase is a regulator of vascular smooth muscle contraction. Antioxid Redox Signal. 2011;14(4):543-8.
3. Ho H, Cheng M, Chiu DT. G6PD-an old bottle with new wine. Chang Gung Med J. 2005;28(9):606-12.
4. Ho HY, Cheng ML, Chiu DT. Glucose-6-phosphate dehydrogenase-from oxidative stress to cellular functions and degenerative diseases. Redox Rep. 2007;12(3):109-18.
5. Wan GH, Tsai SC, Chiu DT. Decreased blood activity of glucose-6-phosphate dehydrogenase associates with increased risk for diabetes mellitus. Endocrine. 2002;19(2):191-5.
6. Peiretti E, Mandas A, Cocco P, Norfo C, Abete C, Angius F, et al. Glucose-6-phosphate-dehydrogenase deficiency as a risk factor for pterygium. Invest Ophthalmol Vis Sci. 2010;51(6):2928-35.
7. Beutler E. Glucose-6-phosphate dehydrogenase deficiency and other red cell enzyme abnormalities. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams Hematology. 6th ed. New York: McGraw-Hill; 2001. p. 527-47.
8. Devi AS, Helen R, Vanamala A, Chaithra V, Karuna R. Screening for G6PD deficiency in blood donor population. Indian J Hematol Blood Transfus. 2010;26(3):122-3.
9. Prchal JT, Gregg XT. Red cell enzymes. Hematology Am Soc Hematol Educ Program. 2005;2005(1):19-23.
10. Fico A, Paglialunga F, Cigliano L, Abrescia P, Verde P, Martini G, et al. Glucose-6-phosphate dehydrogenase plays a crucial role in protection from redox-stress-induced apoptosis. Cell Death Differ. 2004;11(8):823-31.
11. Sadler JM Jr, Ash S, Brito-Babapulle FM. Possible fenugreek induced haemolysis in a patient with previously unknown G6PD deficiency. BMJ Case Rep. 2009;pii:bcr09.2008.0895.
12. Kim J, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci. 2005;30(3):142-50.
13. Meloni L, Manca MR, Loddo I, Cioglia G, Cocco P, Schwartz A, et al. Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease. J Inherit Metab Dis. 2008;31(3):412-7.
14. Pinna A, Solinas G, Masia C, Zinellu A, Carru C, Carta A. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in nonarteritic anterior ischemic optic neuropathy in a Sardinian population, Italy. Invest Ophthalmol Vis Sci. 2008;49(4):1328-32.
15. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408(6809):239-47.
16. Park J, Choe SS, Choi AH, Kim KH, Yoon MJ, Suganami T, et al. Increase in glucose-6-phosphate dehydrogenase in adipocytes stimulates oxidative stress and inflammatory signals. Diabetes. 2006; 55(11):2939-49.
17. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599-622.
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism. Arthritis Rheum. 2010;62(9):2569-81.
19. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-8.
20. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
21. Prevoo MLL, Hof van't MA, Kuper HH, Leeuwen van MA, Putte van de LBA, Riel van PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
22. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, et al. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56(7):2223-31.
23. Beutler E. Red Cell Metabolism Manual of Biochemical Methods. London: Academic Press; 1971. p. 68-70.
24. Hassan SZ, Gheita TA, Kenawy SA, Fahim AT, El-Sorougy IM, Abdou MS. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis. 2011;14(4):325-31.
25. Beutler E, Vulliamy TJ. Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis. 2002; 28(2):93-103.
26. Moiz B, Nasir A, Moatter T, Naqvi ZA, Khurshid M. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in Pakistani population. Int J Lab Hematol. 2011;33(6):570-8.
27. Cattaneo G, Galvagno G, Mussa F. Kawasaki disease in a subject with G6PD deficiency. Pediatr Med Chir. 1989;11(2):219-21.
28. Chen CH, Lin LY, Yang KD, Hsieh KS, Kuo HC. Kawasaki disease with G6PD deficiency-Report of one case and literature review. J Microbiol Immunol Infect. 2012 Jun 22. [Epub ahead of print]
29. Khurana V, Bradley TP. Adult-onset Still's disease associated with G6PD deficiency: a case report and literature review. J Assoc Acad Minor Phys. 1998;9(3):56-8.
30. Nahir AM, Vitis N, Silbermann M. Cellular enzymatic activities in the articular cartilage of osteoarthritic and osteoporotic hip joints of humans: a quantitative cytochemical study. Aging (Milano). 1990;2(4):363-9.
31. Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. Hum Hered. 2000;50(3):158-61.
32. White JM, Byrne M, Richards R, Buchanan T, Katsoulis E, Weerasingh K. Red cell genetic abnormalities in Peninsular Arabs: sickle haemoglobin, G6PD deficiency, and alpha and beta thalassaemia. J Med Genet. 1986;23(3):245-51.
33. White JM, Christie BS, Nam D, Daar S, Hidds DR. Frequency and clinical significance of erythrocyte genetic abnormalities in Omanis. J Med Genet. 1993;30(5):396-400.
34. Oppenheim A, Jury CL, Rund D, Vulliamy TJ, Luzzatto L. G6PD Mediterranean accounts for the high prevalence of G6PD in Kurdish Jews. Hum Genet. 1993;91(3):293-4.
35. Jiang WY, Zhou BY, Yu GL, Liu H, Zeng JB, Lin QD, et al. G6PD Genotype and its associated enzymatic activity in a Chinese population. Biochem Genet. 2012;50(1-2):34-44.
36. Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar J. 2011;10(1):241.
37. Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, et al. High risk of severe anaemia after Chlorproguanil-Dapsone + Artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS ONE. 2008;3(12):e4031.
38. Hassan SZ, Gheita TA, Kenawy SA, Fahim AT, El-Sorougy IM, Abdou MS. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis. 2011;14(4):325-31.
39. Carette C, Dubois-Laforgue D, Gautier JF, Timsit J. Diabetes mellitus and glucose-6-phosphate dehydrogenase deficiency: from one crisis to another. Diabetes Metab. 2011;37(1):79-82.
40. Zhang Z, Liew CW, Handy DE, Zhang Y, Leopold JA, Hu J, et al. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J. 2010;24(5): 1497-505.
41. Emamghorashi F, Hoshmand F, Mohtashamifar A. Screening for glucose-6-phosphate dehydrogenase deficiency in blood donors. Hematology. 2010;15(2):122-4.